BioCentury | May 31, 2010
Finance

Performance Counts

...$275.3 Specialty pharma: cardiovascular and metabolic disorders Other M&A Target Acquirer Acq value Raised Focus AdProTech Ltd....
BioCentury | Aug 2, 2004
Company News

Inflazyme autoimmune, inflammation news

...Positions will be cut across the combined operations of the company and its recent acquisition, Adprotech Ltd....
BioCentury | Apr 26, 2004
Company News

AdProTech, Inflazyme deal

...IZP completed its previously announced acquisition of Adprotech for 12.7 million shares, valued at C$18.4 million...
...C$1.45 on April 20. The deal was announced earlier this month (see BioCentury, April 12). Adprotech Ltd....
BioCentury | Apr 12, 2004
Company News

AdProTech, Inflazyme, Avant deal

...technology platform in complement inhibition, and Adprotech's Prodaptin drug targeting system. The deal also includes Adprotech's...
...solid organ transplantation. On closing, Adprotech shareholders will hold about 12% of IZP's outstanding shares. Adprotech...
...licensed to Adprotech certain components of its IP that cover complement inhibition. The license enables Adprotech...
BioCentury | Apr 8, 2004
Company News

Inflazyme acquiring Adprotech

...Inflazyme (TSE:IZP) said it will acquire Adprotech (Cambridge, U.K.) in a stock deal worth about C$20...
...inflammation technology platform in complement inhibition, and Adprotech's Prodaptin drug-targeting system. The deal also includes Adprotech's...
...the merged company. Upon closing, Adprotech shareholders will hold about 12% of IZP's outstanding shares. Adprotech...
BioCentury | Aug 4, 2003
Strategy

Clinical leaders

...diagnostic products Company Status Country Active Biotech (CSE:ACTIB) Ph II Sweden Addex Ph II Switzerland AdProTech...
BioCentury | Jun 30, 2003
Clinical News

APT070 genetically modified fragment of anti-CD35 antibody regulatory update

...The FDA granted Orphan Drug designation to Adprotech's APT070 to prevent delayed graft function in solid...
...2002. The compound is in Phase II testing for the indication and for rheumatoid arthritis. Adprotech Ltd....
BioCentury | May 19, 2003
Product Development

RA rally

...104838 Anti-TNF antisense inhibitor Ph II Elan Roche MRA IL-6 receptor antagonist Ph II Chugai Adprotech...
BioCentury | May 12, 2003
Finance

Europe's top decile & quartile

...Gyros $29.3 De Novo $28.3 Affibody $28.0 Lorantis $27.9 Munich $27.8 Paion $27.3 Graffinity $27.2 AdProTech...
BioCentury | Mar 3, 2003
Clinical News

APT070: Phase IIa

...study in 45 transplant patients. APT070 also is in Phase II testing for rheumatoid arthritis. Adprotech Ltd....
Items per page:
1 - 10 of 25
BioCentury | May 31, 2010
Finance

Performance Counts

...$275.3 Specialty pharma: cardiovascular and metabolic disorders Other M&A Target Acquirer Acq value Raised Focus AdProTech Ltd....
BioCentury | Aug 2, 2004
Company News

Inflazyme autoimmune, inflammation news

...Positions will be cut across the combined operations of the company and its recent acquisition, Adprotech Ltd....
BioCentury | Apr 26, 2004
Company News

AdProTech, Inflazyme deal

...IZP completed its previously announced acquisition of Adprotech for 12.7 million shares, valued at C$18.4 million...
...C$1.45 on April 20. The deal was announced earlier this month (see BioCentury, April 12). Adprotech Ltd....
BioCentury | Apr 12, 2004
Company News

AdProTech, Inflazyme, Avant deal

...technology platform in complement inhibition, and Adprotech's Prodaptin drug targeting system. The deal also includes Adprotech's...
...solid organ transplantation. On closing, Adprotech shareholders will hold about 12% of IZP's outstanding shares. Adprotech...
...licensed to Adprotech certain components of its IP that cover complement inhibition. The license enables Adprotech...
BioCentury | Apr 8, 2004
Company News

Inflazyme acquiring Adprotech

...Inflazyme (TSE:IZP) said it will acquire Adprotech (Cambridge, U.K.) in a stock deal worth about C$20...
...inflammation technology platform in complement inhibition, and Adprotech's Prodaptin drug-targeting system. The deal also includes Adprotech's...
...the merged company. Upon closing, Adprotech shareholders will hold about 12% of IZP's outstanding shares. Adprotech...
BioCentury | Aug 4, 2003
Strategy

Clinical leaders

...diagnostic products Company Status Country Active Biotech (CSE:ACTIB) Ph II Sweden Addex Ph II Switzerland AdProTech...
BioCentury | Jun 30, 2003
Clinical News

APT070 genetically modified fragment of anti-CD35 antibody regulatory update

...The FDA granted Orphan Drug designation to Adprotech's APT070 to prevent delayed graft function in solid...
...2002. The compound is in Phase II testing for the indication and for rheumatoid arthritis. Adprotech Ltd....
BioCentury | May 19, 2003
Product Development

RA rally

...104838 Anti-TNF antisense inhibitor Ph II Elan Roche MRA IL-6 receptor antagonist Ph II Chugai Adprotech...
BioCentury | May 12, 2003
Finance

Europe's top decile & quartile

...Gyros $29.3 De Novo $28.3 Affibody $28.0 Lorantis $27.9 Munich $27.8 Paion $27.3 Graffinity $27.2 AdProTech...
BioCentury | Mar 3, 2003
Clinical News

APT070: Phase IIa

...study in 45 transplant patients. APT070 also is in Phase II testing for rheumatoid arthritis. Adprotech Ltd....
Items per page:
1 - 10 of 25